Covid19LSH1394NCT04948190
Canine COVID-19 Detection Phase 2 and 3
An observational study of Covid19 and SARS-CoV2 Infection, run by ARCTEC at 1 site in United Kingdom.
Trial summary
The purpose of this study is to determine whether trained medical detection dogs can accurately detect the presence of COVID-19 in people infected with the virus, or using samples of their clothing or body odour. Read more about this study
- Who is it for?
- Ages 16 years and olderHealthy volunteers can take part
- Conditions the study is for
- Covid19, SARS-CoV2 Infection
- What is being tested?
- Testing with medical detection dogs
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 11,015 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 8 Mar 2021to 27 Sep 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Phase 2 parts 1 and 2: Study population will comprise SARS-CoV-2 negative volunteers. Phase 2 part 3: Study population will comprise SARS-CoV-2 positive volunteers living locally to Milton Keynes. Phase 2 part 4: Study population will comprise attendees or passengers at relevant field location. Phase 2 part 5: Study population will consist of stakeholders appropriate to the field location used in phase 2 part 4. Phase 3: Volunteers who are seeking testing for COVID-19, or who have been tested in the past 4 days.
Who may be able to join
- Phase 2, training part 1 \& 2
- Adult male or female, aged 16 years or over.
- Written (hard copy or electronic) or verbal informed consent provided.
- Willing and able to wear or carry clothing (e.g. t-shirt) collected as part of Phase 1 from an individual infected with SARS-CoV-2 or an individual not infected with SARS-CoV-2.
- Has declared non-symptomatic 7 days (as defined by the latest NHS guidance) prior to participation in the training exercise.
- Would be willing to have a SARS-CoV-2 test within 24 h of the training exercise if required.
Show all 30Show fewer
- Phase 2, training part 3
- Adult male or female, aged 16 years or over.
- Written (hard copy or electronic) or verbal informed consent provided.
- Has received a positive result for SARS-CoV-2 from a test conducted within the past 5 days. or is experiencing SARS-CoV-2 symptoms.
- Willing and able to share, or grant access to, their SARS-CoV-2 test result.
- Has access to private outdoor space (e.g. front garden, driveway), reachable without leaving the location where the participant is self-isolating.
- Is asymptomatic or mildly ill (i.e. not requiring hospitalisation, able to walk short distances and stand for up to 15 minutes).
- Phase 2 part 4, acceptability and feasibility study
- Adult male or female, aged 16 years or over.
- Written (hard copy or electronic) or verbal informed consent provided.
- Would be willing to have a SARS-CoV-2 test within 72 hours of the training exercise if required.
- Willing and able to share, or grant access to their SARS-CoV-2 test result.
- Phase 2 part 5, Criteria for all volunteers
- Adult male or female, aged 16 years or over
- Electronic informed consent provided
- Additional criteria for volunteers participating in focus groups
- Adult male or female, aged 16 years or over.
- Written (hard copy or electronic) or verbal informed consent provided.
- Able to access online video-conferencing tools (such as Zoom or Teams).
- Phase 3, Deployment testing
- Adult male or female, aged 16 years or over.
- Willing and able to have a SARS-CoV-2 test within 96 h of participation in the deployment exercise.
- Willing and able to share, or grant access to, their SARS-CoV-2 test result.
- Verbal or written (hard copy or electronic) informed consent provided by the participant.
Who cannot join
- Phase 2, training part 1 \& 2
- Younger than 16 years old
- Informed consent not provided
- Unwilling or unable to wear or carry clothing from an individual infected or uninfected with SARS-CoV-2.
- Has not declared non-symptomatic within 7 days prior to the training exercise.
- Is unwilling or unable to have a SARS-CoV-2 test within 24 hours of the training exercise if required.
Show all 28Show fewer
- Phase 2, training part 3
- Adult male or female, aged under 16 years.
- Informed consent not provided.
- Has not received a positive result for SARS-CoV-2 or experiencing SARS-CoV-2 symptoms.
- Unwilling or unable to share, or grant access to their SARS-CoV-2 test result.
- Has no access to private outdoor space.
- Participant requires hospitalisation or is unable to walk short distances and stand for up to 15 minutes.
- Phase 2 part 4, acceptability and feasibility study
- Adult male or female, aged under 16 years.
- Informed consent not provided.
- Unwilling or unable to have a SARS-CoV-2 test within 72 hours of the training exercise if required.
- Unwilling or unable to share, or grant access to their SARS-CoV-2 test result. Phase 2 part 5 Criteria for all volunteers
- Adult male or female, aged under 16 years.
- Informed consent not provided Additional criteria for volunteers participating in focus groups.
- Adult male or female, aged under 16 years · Informed consent not provided.
- Unable to access online video-conferencing tools (such as Zoom or Teams)
- Phase 3 Deployment testing
- Adult male or female, aged under 16 years
- Informed consent not provided.
- Unwilling or unable to have a SARS-CoV-2 test within 96 hours of participation in the deployment exercise.
- Unwilling or unable to provide a scent swab.
- Unwilling or unable to share, or grant access to, their SARS-CoV-2 test result.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site, 1 recruiting
- Recruiting
Arctec at London School of Hygiene & Tropical Medicine
London, WC1E 7HT
Sarah Dewhirst, PhD, +440209278190 ext. +440209278190, sarah.dewhirst@lshtm.ac.uk
Manil Shah, MSc, arctec@lshtm.ac.uk
About this study
Official title: Using Medical-detection Dogs to Identify People With SARS-CoV-2. Phase 2 and 3 -Training Dogs to Detect People Infected With SARS-CoV-2.
The purpose of this study is to determine whether trained medical detection dogs can accurately detect the presence of COVID-19 in people infected with the virus, or using samples of their clothing or body odour.
The study will train dogs to identify and discriminate between individuals wearing clothing collected from people infected with SARS-CoV-2 and uninfected individuals under semi-field conditions.Following this training, field testing will be used to determine whether trained dogs can distinguish between people infected with SARS-CoV-2 and uninfected individuals, producing estimates of dogs' sensitivity and specificity.
Read the detailed description
When the COVID-19 epidemic wanes it will be important to prevent outbreaks of, and the reintroduction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the country, since there will be many susceptible individuals remaining in the population. In order to prevent third and further waves of COVID-19, it will be important to screen passengers arriving from high-risk countries. This task would be made simpler if a rapid non-invasive method were available for detecting infected individuals, particularly those with asymptomatic, pre-symptomatic or prodromal symptomatic infections with SARS-CoV-2 from those individuals who are not carrying the virus.
Thermal screening, practised in many airports and ports around the world, has a low sensitivity since not all patients develop fever. Consequently, it has received considerable criticism in some quarters. The use of trained dogs could provide a rapid primary screen for detecting those potentially carrying the SARS-CoV-2 virus. Travellers indicated by the dogs as likely to be carrying the virus would then be tested by nasal and throat swabs, with diagnosis confirmed/excluded using real-time RT-PCR or an accurate rapid diagnostic test according to Government Guidelines. Using trained dogs would enable extremely rapid screening, with each dog able to assess up to 250 travellers per hour, saving time and money.
There is evidence that viral and bacterial respiratory infections cause the release of specific odours from human cells. Other work with detection dogs has found dogs can detect and learn the smell of virus-associated volatiles in real time, with sensitivities of up to 96% and specificity of up to 98%. The current study will build further investigate whether trained dogs can differentiate between odours associated with viral infections.
In Phase 1 of this study (Clinical Trials ref: NCT04509713), the investigators hypothesised that dogs, with their highly advanced sense of smell could be trained to detect people infected with the SARS-CoV-2 virus. Medical Detection Dogs were trained and tested using stand trials with clothing samples worn by people who had variously tested positive or negative for SARS-CoV-2 in RT-PCR tests.
In Phase 2, the clothing collected in Phase 1 will be used to train and transition the dogs from Phase 1, where they identified samples in the laboratory environment, to semi-field settings. Phase 1 clothing samples will be worn by human volunteers in a series of 'line-up' trials, under increasingly complex settings. As part of phase 2, study staff will opportunistically conduct line-up tests with volunteers confirmed to be infected with SARS-CoV-2, to allow dogs to learn the whole-body odour of infection.
Phase 3 will take place once the investigators have demonstrated the dogs can work within a real-world environment (Phase 2 above). In this phase, trainers will deploy the dogs and evaluate performance through in use testing. This will be done at a suitable venue, most likely a COVID-19 testing centre, airport or university, to ensure a high enough rate of potential positive individuals.
- Conditions
- Covid19, SARS-CoV2 Infection
- Being tested
- Testing with medical detection dogs
- Keywords
- Medical Detection Dog, Canine
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Testing with medical detection dogsBehavioural
Participants will be screened by medical detection dogs. In phase 2, participants may be asked to wear clothing samples collected in phase 1, as part of dog training procedures. In subsequent study parts, participants will wear their own clothing.
| Study group | Role | What they receive |
|---|---|---|
| SARS-CoV-2 Infected/ positive group | Has tested positive for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages). Aged 16 years or older, willing and able to provide informed consent. Receives: Behavioral: Testing with medical detection dogs | |
| SARS-CoV-2 negative group | Has tested negative for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages, and in phase 2 part 1, 2 and 4 enrolment may be accepted using symptoms-based criteria). Aged 16 years or older, willing and able to provide informed consent. Receives: Behavioral: Testing with medical detection dogs |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase 2: Sensitivity of dogs detecting COVID-19 on worn clothing samples.
The phase 2 study section is designed to measure the sensitivity of the dogs to detect participants infected with SARS-CoV-2 using clothing samples.
During testing the reaction of each dog to a positive sample will be observed (i.e. standing, sitting or lying down). The dog's diagnostic accuracy will then be determined in a double-blinded study. Here the trainer and technician using the computer to record the results of the study are blinded to the identity of each sample until the trainer calls the final decision (positive or negative) based on the response of the dog to the sample.
This outcome will assess dogs' sensitivity in screening clothing samples collected in an earlier trial, and worn by volunteers, all of whom are expected to be SARS-CoV-2 negative.
Sensitivity will be calculated against 'gold standard' of RT-PCR test outcomes.
Measured: 6 weeks
Phase 2: Specificity of dogs detecting COVID-19 on worn clothing samples.
The phase 2 study section is designed to measure the specificity of the dogs to detect participants infected with SARS-CoV-2 using clothing samples.
During testing the reaction of each dog to a positive sample will be observed (i.e. standing, sitting or lying down). The dog's diagnostic accuracy will then be determined in a double-blinded study. Here the trainer and technician using the computer to record the results of the study are blinded to the identity of each sample until the trainer calls the final decision (positive or negative) based on the response of the dog to the sample.
This outcome will assess dogs' specificity in screening clothing samples collected in an earlier trial, and worn by volunteers, all of whom are expected to be SARS-CoV-2 negative.
Specificity will be calculated against 'gold standard' of RT-PCR test outcomes.
Measured: 6 weeks
Phase 3: Specificity precision of dogs to detect COVID-19 in humans in semi-field settings.
The phase 3 study section will measure the sensitivity of the dogs in detection of SARS-CoV-2 on human participants in semi-field settings.
During screening the reaction of each dog to an individual being screened will be observed (i.e. standing, sitting or lying down).
The dog's diagnostic sensitivity will be calculated by comparing these indications against outcomes of RT-PCR tests, which must be conducted within 96 hours of test participation. Testing will be conducted under double-blinded conditions.
This outcome will assess dogs' sensitivity on in-person volunteers, screened in semi-field settings. Volunteers will comprise both SARS-CoV-2 positive and SARS-CoV-2 negative individuals.
Sensitivity will be calculated to +/- 5% accuracy. Sensitivity= percentage of true positives correctly identified by dogs.
Measured: 20 weeks (overlapping with phase 2)
Phase 3: Specificity precision of dogs to detect COVID-19 in humans in semi-field settings.
The phase 3 study section will measure the specificity of the dogs in detection of SARS-CoV-2 on human participants in semi-field settings.
During screening the reaction of each dog to an individual being screened will be observed (i.e. standing, sitting or lying down).
The dog's diagnostic specificity will be calculated by comparing these indications against outcomes of RT-PCR tests, which must be conducted within 96 hours of test participation. Testing will be conducted under double-blinded conditions.
This outcome will assess dogs' specificity on in-person volunteers, screened in semi-field settings. Volunteers will comprise both SARS-CoV-2 positive and SARS-CoV-2 negative individuals.
Specificity will be calculated to +/- 5% accuracy. Specificity= percentage of true negatives correctly identified by dogs.
Measured: 20 weeks (overlapping with phase 2)
Secondary outcomes (1)
Qualitative outcome: acceptability of dogs as a screening tool
Interviews and focus groups involving stakeholder groups will be used to assess acceptability of dogs as a disease-screening tool.
Eligible volunteers belonging to relevant groups will be invited to a single event (either interview with researcher, or focus group with other volunteers from same group type). Concept of dogs as a screening tool will be explained, using verbal overview, and where possible photos or videos.
Volunteers will be asked to share their views on acceptability of dogs as a screening tool. Key quotes will be noted from each session. At the conclusion of all sessions, key themes and opinions will be drawn from session notes, and reported using illustrative quotes where appropriate.
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2021
- Study start8 Mar 2021
- Primary completion30 Aug 2021 (estimated)
- Study completion27 Sep 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Other
- Enrolment
- 11,015 participants (estimated)
Sponsor and investigators
- Lead sponsor
- ARCTEC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Durham University, Cardiff University, Medical Detection Dogs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04948190
- Sponsor's protocol ID
- LSH1394
- Acronym
- LSH1394
- Status last verified
- Jul 2021
- First submitted
- 28 Jun 2021
- Last updated
- 30 Jul 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Using Medical-detection Dogs to Identify People With SARS-CoV-2. Phase 2 and 3 -Training Dogs to Detect People Infected With SARS-CoV-2.
- ClinicalTrials.gov ID
- NCT04948190
- Acronym / sponsor ID
- LSH1394 / LSH1394
- Conditions
- Covid19, SARS-CoV2 Infection
- Keywords
- Medical Detection Dog, Canine
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 11,015 participants (estimated)
- Lead sponsor
- ARCTECIndustry (pharma, biotech, devices)
- Collaborators
- Durham University, Cardiff University, Medical Detection Dogs
- Study start
- 8 Mar 2021 (actual)
- Primary completion
- 30 Aug 2021 (estimated)
- Study completion
- 27 Sep 2021 (estimated)
- First posted
- 1 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether trained medical detection dogs can accurately detect the presence of COVID-19 in people infected with the virus, or using samples of their clothing or body odour.
The study will train dogs to identify and discriminate between individuals wearing clothing collected from people infected with SARS-CoV-2 and uninfected individuals under semi-field conditions.Following this training, field testing will be used to determine whether trained dogs can distinguish between people infected with SARS-CoV-2 and uninfected individuals, producing estimates of dogs' sensitivity and specificity.
Detailed description
When the COVID-19 epidemic wanes it will be important to prevent outbreaks of, and the reintroduction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the country, since there will be many susceptible individuals remaining in the population. In order to prevent third and further waves of COVID-19, it will be important to screen passengers arriving from high-risk countries. This task would be made simpler if a rapid non-invasive method were available for detecting infected individuals, particularly those with asymptomatic, pre-symptomatic or prodromal symptomatic infections with SARS-CoV-2 from those individuals who are not carrying the virus.
Thermal screening, practised in many airports and ports around the world, has a low sensitivity since not all patients develop fever. Consequently, it has received considerable criticism in some quarters. The use of trained dogs could provide a rapid primary screen for detecting those potentially carrying the SARS-CoV-2 virus. Travellers indicated by the dogs as likely to be carrying the virus would then be tested by nasal and throat swabs, with diagnosis confirmed/excluded using real-time RT-PCR or an accurate rapid diagnostic test according to Government Guidelines. Using trained dogs would enable extremely rapid screening, with each dog able to assess up to 250 travellers per hour, saving time and money.
There is evidence that viral and bacterial respiratory infections cause the release of specific odours from human cells. Other work with detection dogs has found dogs can detect and learn the smell of virus-associated volatiles in real time, with sensitivities of up to 96% and specificity of up to 98%. The current study will build further investigate whether trained dogs can differentiate between odours associated with viral infections.
In Phase 1 of this study (Clinical Trials ref: NCT04509713), the investigators hypothesised that dogs, with their highly advanced sense of smell could be trained to detect people infected with the SARS-CoV-2 virus. Medical Detection Dogs were trained and tested using stand trials with clothing samples worn by people who had variously tested positive or negative for SARS-CoV-2 in RT-PCR tests.
In Phase 2, the clothing collected in Phase 1 will be used to train and transition the dogs from Phase 1, where they identified samples in the laboratory environment, to semi-field settings. Phase 1 clothing samples will be worn by human volunteers in a series of 'line-up' trials, under increasingly complex settings. As part of phase 2, study staff will opportunistically conduct line-up tests with volunteers confirmed to be infected with SARS-CoV-2, to allow dogs to learn the whole-body odour of infection.
Phase 3 will take place once the investigators have demonstrated the dogs can work within a real-world environment (Phase 2 above). In this phase, trainers will deploy the dogs and evaluate performance through in use testing. This will be done at a suitable venue, most likely a COVID-19 testing centre, airport or university, to ensure a high enough rate of potential positive individuals.
Study design
- Observational model
- Case-control
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SARS-CoV-2 Infected/ positive group | – | Behavioral: Testing with medical detection dogsHas tested positive for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages). Aged 16 years or older, willing and able to provide informed consent. |
| SARS-CoV-2 negative group | – | Behavioral: Testing with medical detection dogsHas tested negative for SARS-CoV-2 within appropriate timeframe (criteria vary for different study stages, and in phase 2 part 1, 2 and 4 enrolment may be accepted using symptoms-based criteria). Aged 16 years or older, willing and able to provide informed consent. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Phase 2 parts 1 and 2: Study population will comprise SARS-CoV-2 negative volunteers. Phase 2 part 3: Study population will comprise SARS-CoV-2 positive volunteers living locally to Milton Keynes. Phase 2 part 4: Study population will comprise attendees or passengers at relevant field location. Phase 2 part 5: Study population will consist of stakeholders appropriate to the field location used in phase 2 part 4. Phase 3: Volunteers who are seeking testing for COVID-19, or who have been tested in the past 4 days.
Key inclusion criteria (30 listed)
- Phase 2, training part 1 \& 2
- Adult male or female, aged 16 years or over.
- Written (hard copy or electronic) or verbal informed consent provided.
- Willing and able to wear or carry clothing (e.g. t-shirt) collected as part of Phase 1 from an individual infected with SARS-CoV-2 or an individual not infected with SARS-CoV-2.
- Has declared non-symptomatic 7 days (as defined by the latest NHS guidance) prior to participation in the training exercise.
Key exclusion criteria (28 listed)
- Phase 2, training part 1 \& 2
- Younger than 16 years old
- Informed consent not provided
- Unwilling or unable to wear or carry clothing from an individual infected or uninfected with SARS-CoV-2.
- Has not declared non-symptomatic within 7 days prior to the training exercise.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Testing with medical detection dogsParticipants will be screened by medical detection dogs. In phase 2, participants may be asked to wear clothing samples collected in phase 1, as part of dog training procedures. In subsequent study parts, participants will wear their own clothing. | Behavioural | SARS-CoV-2 Infected/ positive group, SARS-CoV-2 negative group |
Primary outcome
Phase 2: Sensitivity of dogs detecting COVID-19 on worn clothing samples.
Time frame: 6 weeks
The phase 2 study section is designed to measure the sensitivity of the dogs to detect participants infected with SARS-CoV-2 using clothing samples. During testing the reaction of each dog to a positive sample will be observed (i.e. standing, sitting or lying down). The dog's diagnostic accuracy will then be determined in a double-blinded study. Here the trainer and technician using the computer to record the results of the study are blinded to the identity of each sample until the trainer calls the final decision (positive or negative) based on the response of the dog to the sample. This outcome will assess dogs' sensitivity in screening clothing samples collected in an earlier trial, and worn by volunteers, all of whom are expected to be SARS-CoV-2 negative. Sensitivity will be calculated against 'gold standard' of RT-PCR test outcomes.
Phase 2: Specificity of dogs detecting COVID-19 on worn clothing samples.
Time frame: 6 weeks
The phase 2 study section is designed to measure the specificity of the dogs to detect participants infected with SARS-CoV-2 using clothing samples. During testing the reaction of each dog to a positive sample will be observed (i.e. standing, sitting or lying down). The dog's diagnostic accuracy will then be determined in a double-blinded study. Here the trainer and technician using the computer to record the results of the study are blinded to the identity of each sample until the trainer calls the final decision (positive or negative) based on the response of the dog to the sample. This outcome will assess dogs' specificity in screening clothing samples collected in an earlier trial, and worn by volunteers, all of whom are expected to be SARS-CoV-2 negative. Specificity will be calculated against 'gold standard' of RT-PCR test outcomes.
Phase 3: Specificity precision of dogs to detect COVID-19 in humans in semi-field settings.
Time frame: 20 weeks (overlapping with phase 2)
The phase 3 study section will measure the sensitivity of the dogs in detection of SARS-CoV-2 on human participants in semi-field settings. During screening the reaction of each dog to an individual being screened will be observed (i.e. standing, sitting or lying down). The dog's diagnostic sensitivity will be calculated by comparing these indications against outcomes of RT-PCR tests, which must be conducted within 96 hours of test participation. Testing will be conducted under double-blinded conditions. This outcome will assess dogs' sensitivity on in-person volunteers, screened in semi-field settings. Volunteers will comprise both SARS-CoV-2 positive and SARS-CoV-2 negative individuals. Sensitivity will be calculated to +/- 5% accuracy. Sensitivity= percentage of true positives correctly identified by dogs.
Phase 3: Specificity precision of dogs to detect COVID-19 in humans in semi-field settings.
Time frame: 20 weeks (overlapping with phase 2)
The phase 3 study section will measure the specificity of the dogs in detection of SARS-CoV-2 on human participants in semi-field settings. During screening the reaction of each dog to an individual being screened will be observed (i.e. standing, sitting or lying down). The dog's diagnostic specificity will be calculated by comparing these indications against outcomes of RT-PCR tests, which must be conducted within 96 hours of test participation. Testing will be conducted under double-blinded conditions. This outcome will assess dogs' specificity on in-person volunteers, screened in semi-field settings. Volunteers will comprise both SARS-CoV-2 positive and SARS-CoV-2 negative individuals. Specificity will be calculated to +/- 5% accuracy. Specificity= percentage of true negatives correctly identified by dogs.
1 secondary outcome
Qualitative outcome: acceptability of dogs as a screening tool
Time frame: 8 weeks
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2021.
- Individual participant dataSharing planned: No
Related trials for Covid19
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
RecruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruitingObservational study
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19 and SARS-CoV2 Infection, run by ARCTEC at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 30 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact James L Logan, PhD (0207 927 2008, james.logan@lshtm.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phase 2: Sensitivity of dogs detecting COVID-19 on worn clothing samples. (time frame: 6 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2021.